XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
Assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 were as follows (in thousands):
March 31, 2021
Level 1Level 2Level 3Total
(unaudited)
Money market funds$125,378 $— $— $125,378 
U.S. Treasury notes49,130 — — 49,130 
Commercial paper— 57,067 — 57,067 
Corporate bonds— 27,610 — 27,610 
Contingent consideration liabilities— — (32,444)(32,444)
Total
$174,508 $84,677 $(32,444)$226,741 
Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 were as follows (in thousands):
December 31, 2020
Level 1Level 2Level 3Total
Money market funds$79,387 $— $— $79,387 
U.S. Treasury notes59,389 — — 59,389 
Commercial paper— 68,018 — 68,018 
Corporate bonds— 48,501 — 48,501 
Asset-backed securities— 3,009 — 3,009 
Contingent consideration liabilities— — (31,264)(31,264)
Total
$138,776 $119,528 $(31,264)$227,040 
There were no transfers between Level 1 and Level 2 during the three months ended March 31, 2021 and 2020.
Convertible Senior Notes
As of March 31, 2021, the estimated fair value of the our convertible senior notes, with aggregate principal totaling $230.0 million, was $391.3 million. We estimate the fair value based on quoted market prices in an inactive market on the last trading day of the reporting period (Level 2). These convertible senior notes are recorded at face value less unamortized debt discount and transaction costs on our consolidated balance sheets. Refer to Note 9 —Convertible Senior Notes for further information.
Level 3 fair value measurements
The Healthfinch acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Healthfinch during an earn-out period that ends on July 31, 2021. The Healthfinch contingent consideration will be paid in a combination of cash and shares of our common stock in the same proportion as the initial acquisition consideration. The Vitalware acquisition consideration includes an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Vitalware during an earn-out period that ended on March 31, 2021. The Vitalware contingent consideration is capped at $30.0 million and will be paid in a combination of approximately 50% cash and 50% in shares of our common stock.
We value the expected contingent consideration and the corresponding liabilities using the Monte Carlo valuation method based on estimates of potential pay-out scenarios. The resulting contingent consideration liabilities are categorized as Level 3 fair value measurements and are remeasured as of each reporting period.
The aggregate intrinsic value of the revenue-based earn-out contingent consideration liabilities is approximately $32.5 million based on a point estimate of our internal forecasting of the ultimate earn-outs that will be earned and our common stock price as of March 31, 2021. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs as of March 31, 2021:

Valuation MethodFair ValueMarket Price of Revenue RiskRevenue VolatilityStock Price Volatility
(unaudited)
Revenue-based earn-out liabilitiesMonte Carlo$32.4 million3%10%41%

The Able Health acquisition consideration included an initial estimate for contingent consideration for shares of our common stock if certain incremental billing targets for Able Health were met during an earn-out period that ended on December 31, 2020. This Able Health earn-out contingent consideration liability was settled during the three months ended March 31, 2021.
The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(unaudited)
Balance as of December 31, 2020
$31,264 
Settlement of contingent consideration(1,009)
Change in fair value of contingent consideration liabilities2,156 
Balance as of March 31, 2021
$32,411